Navigation Links
NIST, Maryland researchers COMMAND a better class of liposomes
Date:4/28/2010

Pop a bubble while washing the dishes and you're likely to release a few drops of water trapped when the soapy sphere formed. A few years ago, researchers at the National Institute of Standards and Technology (NIST) pioneered a method* using a microscopic fluidic (microfluidic) device that exploits the same principle to create liquid-filled vesicles called liposomes from phospholipids, the fat complexes that are the building blocks for animal cell membranes. These structures are valued for their potential use as agents to deliver drugs directly to cancers and other disease cells within the body.

Widespread application of liposomes as artificial drug carriers has been hindered by a number of limiting factors such as inconsistency in size, structural instability and high production costs. In a new study,** the NIST and University of Maryland (UM) researchers have detailed the operation of their liposome manufacturing techniqueknown as COMMAND for COntrolled Microfluidic Mixing And Nanoparticle Determinationin order to maximize its effectiveness. Their goal was to better understand how COMMAND works as it produces liposomes with diameters controlled from about 50 to 150 nanometers (billionths of a meter) that are consistently uniform in size and inexpensively produced in what might be called an "assembly-line-on-a-microchip."

The researchers fabricate the COMMAND microfluidic devices by etching tiny channels into a silicon wafer with the same techniques used for making integrated circuits. In COMMAND, phospholipid molecules dissolved in isopropyl alcohol are fed via a central inlet channel into a "mixer" channel and "focused" into a fluid jet by a water-based solution (that in production would carry a drug or other cargo for the vesicles) added through two side channels. The components blend together as they mix by diffusion across the interfaces of the flowing fluid streams, directing the phospholipid molecules to self-assemble into nanoscale vesicles of controlled size. Different microfluidic device designs and fluid flow conditions were tested to investigate their role in producing liposomes.

The research team found that their liposome manufacturing process fundamentally depends on the flow and mixing of the fluid streams. The size of the liposomes can be "tuned" by manipulating the fluid flow rates, which in combination with the dimensions of the microfluidic device, determine the resulting mixing conditions. A tightly focused stream of phospholipid-carrying alcohol flowing at a slow rate tends to mix quickly with the buffer at the beginning of the mixing channel and forms small vesicles. A loosely focused stream flowing at a fast rate travels farther down the length of the mixing channel, allowing more mixing time and yielding larger vesicles.

The geometry of the channels plays an additional role, the researchers noted, in regulating the speed of production and the quantity and concentration of liposomes manufactured. This may be important for future clinical applications of liposomes as well as the integration of COMMAND into more complicated microchip systems for health care.


'/>"/>

Contact: Michael E. Newman
michael.newman@nist.gov
301-975-3025
National Institute of Standards and Technology (NIST)
Source:Eurekalert  

Related biology news :

1. NIST, NCI bring web 2.0 tools to nanotechnology standards effort
2. NIST, Army researchers pave the way for anthrax spore standards
3. Mondre Energy Partnering with Exeter Associates to Address Energy Issues in Maryland
4. University of Maryland School of Medicine receives $30 million to coordinate stem cell consortium
5. Shifting Sands highlights past, present and future of Maryland coastal bays ecosystem
6. Mount Sinai researchers discover potential treatment for bone death in the hip from osteonecrosis
7. Researchers study effect of yuma desalting plant on Cienega de Santa Clara
8. Weill Cornell researchers find that a single gene is responsible for OCD-like behaviors in mice
9. Gene therapy cures canines of inherited form of day blindness, Penn veterinary researchers say
10. UT Southwestern researchers identify key molecular step to fighting off viruses
11. Vitamin D status not predicted by surrogate markers, UB researchers find
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
NIST, Maryland researchers COMMAND a better class of liposomes
(Date:4/11/2017)... 2017 Research and Markets has announced the ... to their offering. ... eye tracking market to grow at a CAGR of 30.37% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
Breaking Biology News(10 mins):
(Date:4/20/2017)... , April 20, 2017  Eli Lilly and Company ... data evaluating galcanezumab for the prevention of migraine at ... will take place April 22-28, 2017, in ... four abstracts at AAN, including safety and patient outcomes ... associated with a reduction in monthly migraine headache days ...
(Date:4/20/2017)... , ... April 20, 2017 , ... ... sources for advanced technology applications, announced today that Chief Executive Officer (CEO) Debbie ... SEMI is the global industry association connecting the electronics manufacturing supply ...
(Date:4/20/2017)... , April 20, 2017 For ... focuses on novel drug development and clinical research aimed at ... Biostage Inc. (NASDAQ: BSTG), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Kite ... ZIOP ). You can access our complimentary research reports ... ...
(Date:4/19/2017)... ... April 19, 2017 , ... Nobilis Therapeutics Announces Completion of Landmark ... Clinical Data in its Upcoming Post Traumatic Stress Disorder Trial , Nobilis Therapeutics, ... trial assessing efficacy of its NBTX-001, a xenon-based therapeutic in the treatment of Panic ...
Breaking Biology Technology: